New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
ApexOnco Front Page
Recent articles
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company is stepping back in second-line breast cancer.
